Replies to post #909 on Biotech Values

[DewDiligence]

I certainly can’t complain –made almost 30% on OXGN in less than two months.

I will remain on the sidelines until management fully addresses the cardiac-toxicity issue. I expect some pointed questions about this at OXGN’s CC in mid February.

[DewDiligence]

FWIW: I just sold short IMDC.